curacle

큐라클 · 365270

Industrials Commercial Services · KOSDAQ

Small-cap

Market cap US$230M (₩317.4B)

Overview

Curacle is a South Korean biotech company listed on KOSDAQ that develops experimental medicines targeting a root cause of hard-to-treat diseases: the breakdown of the cells lining blood vessels, known as endothelial dysfunction.

Its lead candidate, Rivasterat, is an oral drug being developed for retinal diseases such as diabetic macular edema and wet macular degeneration. The company builds its pipeline through two proprietary drug-discovery platforms, one for small-molecule chemical drugs (SOLVADYS®) and one for biologics (EAGLES®).

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$5.1K

▼ −99.6% YoY

Operating profit · FY2025

−US$12M

Loss widened

Net income · FY2025

−US$13.1M

Loss widened

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$7.5M(₩10.3B)	US$1.2M(₩1.6B)	US$5.1K(₩7.1M)
Operating profit	−US$7.6M(−₩10.5B)	−US$9.2M(−₩12.6B)	−US$12M(−₩16.5B)
Net income	−US$8.4M(−₩11.6B)	−US$10.8M(−₩14.9B)	−US$13.1M(−₩18.1B)

Revenue

FY2023US$7.5M
FY2024US$1.2M
FY2025US$5.1K

Operating profit

FY2023−US$7.6M
FY2024−US$9.2M
FY2025−US$12M

Net income

FY2023−US$8.4M
FY2024−US$10.8M
FY2025−US$13.1M

Key ratios (FY2025)

ROE

-48.8%

Debt/Eq

43.5%

Op. margin

-232393.8%

Net margin

-255057.6%

Rev. YoY

▼ −99.6%

Price charts coming soon

Interactive price history isn't here yet. Would you use it?